Artificial Intelligence In Drug Regulatory Submissions In India

V. Shukla, Manvi Mittal
{"title":"Artificial Intelligence In Drug Regulatory Submissions In India","authors":"V. Shukla, Manvi Mittal","doi":"10.2174/2667337109666230209152153","DOIUrl":null,"url":null,"abstract":"\n\nRegulatory affairs are one of the most crucial connections between the pharmaceutical company and the other stakeholder’s or regulatory agencies such as FDA, EMA, etc. Strategies in drug approval and marketing to assure the quality, safety, and efficacy of the drug follow the guidelines and laws stated under the drug and cosmetic act 1940 and rules 1945. Their primary responsibility is to keep the company in compliance with changing guidelines, which necessitates constant monitoring of the most recent industry updates. Drug regulation is a complex process as every country has its own set of documentation that must be done while regulatory submissions. From drug development and drug approval to drug commercialisation, there is a large amount of documentation that must be completed with accuracy, which can be challenging for the professional to complete, therefore, this leads to the introduction of the concept of big data that can be incorporated which will map the regulations according to 5vs model of big data. Thus, to make it more efficient, we can work big data with artificial intelligence to ease the process using natural language processing. This concept will map all the rules and guidelines together and make a cluster of similar rules together. Now, users can use the tool to locate the data of interest in a single site in a more comprised universal language that can be accessed by any professional to complete the task in the given time schedule.\n","PeriodicalId":72255,"journal":{"name":"Applied drug research, clinical trials and regulatory affairs","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied drug research, clinical trials and regulatory affairs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2667337109666230209152153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Regulatory affairs are one of the most crucial connections between the pharmaceutical company and the other stakeholder’s or regulatory agencies such as FDA, EMA, etc. Strategies in drug approval and marketing to assure the quality, safety, and efficacy of the drug follow the guidelines and laws stated under the drug and cosmetic act 1940 and rules 1945. Their primary responsibility is to keep the company in compliance with changing guidelines, which necessitates constant monitoring of the most recent industry updates. Drug regulation is a complex process as every country has its own set of documentation that must be done while regulatory submissions. From drug development and drug approval to drug commercialisation, there is a large amount of documentation that must be completed with accuracy, which can be challenging for the professional to complete, therefore, this leads to the introduction of the concept of big data that can be incorporated which will map the regulations according to 5vs model of big data. Thus, to make it more efficient, we can work big data with artificial intelligence to ease the process using natural language processing. This concept will map all the rules and guidelines together and make a cluster of similar rules together. Now, users can use the tool to locate the data of interest in a single site in a more comprised universal language that can be accessed by any professional to complete the task in the given time schedule.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度药品监管提交中的人工智能
监管事务是制药公司与其他利益相关者或监管机构(如FDA, EMA等)之间最重要的联系之一。确保药品质量、安全性和有效性的药品批准和营销策略遵循《1940年药品和化妆品法》和《1945年规则》规定的指导方针和法律。他们的主要职责是保持公司遵守不断变化的指导方针,这就需要不断监测最新的行业更新。药物监管是一个复杂的过程,因为每个国家都有自己的一套文件,必须在提交监管文件时完成。从药物开发和药物批准到药物商业化,有大量的文件必须准确地完成,这对专业人员来说是具有挑战性的,因此,这导致引入了可以纳入的大数据概念,它将根据大数据的5vs模型来绘制法规。因此,为了提高效率,我们可以使用人工智能来处理大数据,使用自然语言处理来简化过程。这个概念将所有规则和指导方针映射在一起,并将类似的规则聚集在一起。现在,用户可以使用该工具在单个站点中定位感兴趣的数据,这些数据使用更加复杂的通用语言,任何专业人员都可以访问这些语言,以便在给定的时间表内完成任务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Monitoring Regulatory Compliance within the Pharmaceutical Industry Regulation of Nanomaterials and Nanomedicines for Clinical Application Qualitative Analysis and Anti-oxidant Potential of Ethanolic Extract of Manilkara zapota (L.) P. Royen Leaves The Current Regulatory Environment for Software Used in Medical Devices: A Need for Refined International Strategies A comparative study on approval of follow-on version of Sevelamer Carbonate and Glatiramer Acetate (GA) in US, EU
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1